Clinical Trial

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Study acronym: Neo-CD
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.
Protocol Amendment History 2 changes
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07365592
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Colorectal Cancer
Enrollment 138 participants
Start Date 2026-04-09
Primary Completion 2029-12-01 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-13